SARS-CoV-2 and Cancer: are they really partners in crime ?

Vista sencilla de ítem
dc.creatorvan Dam, Peter A.
dc.creatorHuizing, Manon
dc.creatorMestach, Gino
dc.creatorDierckxsens, Stazie
dc.creatorTjalma, Wiebren
dc.creatorBich Trinh, Xuan
dc.creatorPapadimitriou, Kostantinos
dc.creatorAltintas, Sevilay
dc.creatorVermorken, Jan
dc.creatorVulstekeb, Christof
dc.creatorJanssens, Annelies
dc.creatorBerneman, Zwi
dc.creatorPrenen, Hans
dc.creatorMeuris, Leander
dc.creatorVanden Berghe, Wim
dc.creatorSmits, Evelien
dc.creatorPeeters, Marc
dc.date.accessioned2020-07-24T21:56:55Z
dc.date.available2020-07-24T21:56:55Z
dc.date.created2020-07-11
dc.description.abstractenglishThe outbreak of the SARS-CoV-2 pandemic has overwhelmed health care systems in many countries. The clinical presentation of the SARS-CoV-2 varies between a subclinical or flu-like syndrome to that of severe pneumonia with multi-organ failure and death. Initial reports have suggested that cancer patients may have a higher susceptibility to get infected by the SARS-CoV-2 virus but current evidence remains poor as it is biased by important confounders. Patients with ongoing or recent cancer treatment for advanced active disease, metastatic solid tumors and hematological malignancies are at higher risk of developing severe COVID-19 respiratory disease that requires hospitalization and have a poorer disease outcome compared to individuals without cancer. However it is not clear whether these are independent risk factors, or mainly driven by male gender, age, obesity, performance status, uncontrolled diabetes, cardiovascular disease and various other medical conditions. These often have a greater influence on the probability to die due to SARS-CoV-2 then cancer. Delayed diagnosis and suboptimal cancer management due to the pandemic results in disease upstaging and has considerable impact cancer on specific death rates. Surgery during the peak of the pandemic seems to increase mortality, but there is no convincing evidence that adjuvant systemic cancer therapy and radiotherapy are contraindicated, implicating that cancer treatment can be provided safely after individual risk/benefit assessment and some adaptive measures. Underlying immunosuppression, elevated cytokine levels, altered expression of the angiotensin converting enzyme (ACE-2) and TMPRSS2, and a prothrombotic status may fuel the effects of a SARS-CoV-2 in some cancer patients, but have the potential to be used as biomarkers for severe disease and therapeutic targets. The rapidly expanding literature on COVID-19 should be interpreted with care as it is often hampered by methodological and statistical flaws.spa
dc.format.extent36 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.1016/j.ctrv.2020.102068spa
dc.identifier.issn0305-7372spa
dc.identifier.otherhttps://www.sciencedirect.com/science/article/pii/S0305737220301067spa
dc.identifier.urihttps://hdl.handle.net/20.500.12010/11134
dc.publisherCancer Treatment Reviewseng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectCáncerspa
dc.subject.keywordCancerspa
dc.subject.keywordCytokinesspa
dc.subject.keywordACE2spa
dc.subject.keywordTMPRSS2spa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.titleSARS-CoV-2 and Cancer: are they really partners in crime ?spa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localArtículospa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
1-s2.0-S0305737220301067-main.pdf
Tamaño:
956.25 KB
Formato:
Adobe Portable Document Format
Descripción:
Ver documento
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
2.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Documentos científicos relacionados a la COVID-19

Carrera 4 # 22-61 Teléfono: (+57) 601 242 7030 - 018000111022 Fax: (+57) 601 561 2107 Bogotá D.C., Colombia

Fundación Universitaria de Bogotá Jorge Tadeo Lozano | Vigilada Mineducación

Institución de educación superior privada, de utilidad común, sin ánimo de lucro y su carácter académico es el de Universidad

Reconocimiento personería jurídica: Resolución 2613 del 14 de agosto de 1959 Minjusticia.

Institución de Educación Superior sujeta a inspección y vigilancia por el Ministerio de Educación Nacional.

Software DSpace copyright © 2002-2026 LYRASIS